iRhythm Technologies Presents Large-Scale Data At APHRS/JHRS Showing Consistent Zio ECG Monitoring Performance Across Asian And Non-Asian Populations

• iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions.
• Large-scale analysis of more than 400,000 patients1 supports the consistency and generalizability of Zio long-term ECG monitoring (LTCM) performance across populations; median wear and analyzable time among patients identified as Asian (3.4% of the cohort) were comparable to those of non-Asian patients, and findings were consistent with Zio LTCM performance previously reported in the published CAMELOT2 and AVALON3 studies.

iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced new data presented in a podium session at the 18th Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JHRS) 2025 Joint Scientific Session in Yokohama, Japan, held November 12–15.

The investigators, led by Dr. Hiro Kawata, compared device compliance, performance, arrhythmia detection, and repeat-testing rates between Asians and non-Asians in a large cohort of U.S. patients. The study, titled "Comparative Analysis of Arrhythmia Detection and Clinical Outcomes in Asian and Non-Asian Populations Using Ambulatory Cardiac Monitoring," analyzed 408,470 U.S. patients monitored between 2018 and 2022 using iRhythm's Zio® long-term continuous ECG monitoring (LTCM) service for up to 14 days.

The analysis evaluated whether monitoring performance differs between patient groups, given that racial and cultural differences, including factors such as skin type, skin preparation, device tolerability, and lifestyle, may impact compliance and effectiveness in ambulatory cardiac monitoring.